Norgine B.V.

15.04.2024 – 16:22
Norgine B.V. submits Marketing Authorisation Application via Project Orbis for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma
Amsterdam (ots/PRNewswire) - Norgine B.V. today announced its first marketing authorisation application submissions on 10 April 2024, seeking approval for eflornithine in high-risk neuroblastoma (HRNB), via Project Orbis in Australia, Switzerland and the United Kingdom. This milestone supports Norgine's efforts to ...
more
18.05.2023 – 12:00
European study highlights need to improve the quality of conversations about induction of labour (IoL) in clinical settings
Amsterdam (ots/PRNewswire) - - Almost 1 in 2 women (49%) felt the experience of IoL differed from their expectations - The majority of expectant mothers (65%) did not feel fully involved in choosing which method of IoL they prefer - Findings emphasize the importance of collaborative decision-making between ...
more